Based on the observed anti-lymphoma effects of the novel CXCR4 antagonist WK1, which is CXCR4-specific, the CXCR4–CXCL12-axis represents an interesting therapeutic target for CXCR4+ GCB-DLCBL at advanced disease stage and with potential BM infiltration. This evidence concerns the gene CXCR4 and lymphoma.